Search

Your search keyword '"Pepin J"' showing total 858 results
Start Over Author "Pepin J"
858 results on '"Pepin J"'

8. Republication de : Prise en charge du syndrome d’apnées obstructives du sommeil chez la personne vivant avec un diabète : contexte, dépistage, indications et modalités de traitement. Position de la Société Francophone du Diabète (SFD), de la Société Française de Recherche et Médecine du Sommeil (SFRMS) et de la Société de Pneumologie de Langue Française (SPLF)

Author

Borel, A.-L., Tamisier, R., Böhme, P., Priou, P., Avignon, A., Benhamou, P.-Y., Hanaire, H., Pépin, J.-L., Kessler, L., Valensi, P., Darmon, P., and Gagnadoux, F.

Published
2019
Full Text
View/download PDF

10. Republication de : Prise en charge du syndrome d’apnées obstructives du sommeil chez la personne vivant avec un diabète : contexte, dépistage, indications et modalités de traitement. Position de la Société Francophone du Diabète (SFD), de la Société Française de Recherche et Médecine du Sommeil (SFRMS) et de la Société de Pneumologie de Langue Française (SPLF)

Author

Borel, A.-L., Tamisier, R., Böhme, P., Priou, P., Avignon, A., Benhamou, P.-Y., Hanaire, H., Pépin, J.-L., Kessler, L., Valensi, P., Darmon, P., and Gagnadoux, F.

Published
2018
Full Text
View/download PDF

11. Nocturnal hypoxemia, blood pressure, vascular status and chronic mountain sickness in the highest city in the world

Author

Perger, E, Baillieul, S, Esteve, F, Pichon, A, Bilo, G, Soranna, D, Doutreleau, S, Savina, Y, Ulliel-Roche, M, Brugniaux, J, Stauffer, E, Oberholzer, L, Howe, C, Hannco, I, Lombardi, C, Tamisier, R, Pepin, J, Verges, S, Parati, G, Perger E., Baillieul S., Esteve F., Pichon A., Bilo G., Soranna D., Doutreleau S., Savina Y., Ulliel-Roche M., Brugniaux J. V., Stauffer E., Oberholzer L., Howe C., Hannco I., Lombardi C., Tamisier R., Pepin J. -L., Verges S., Parati G., Perger, E, Baillieul, S, Esteve, F, Pichon, A, Bilo, G, Soranna, D, Doutreleau, S, Savina, Y, Ulliel-Roche, M, Brugniaux, J, Stauffer, E, Oberholzer, L, Howe, C, Hannco, I, Lombardi, C, Tamisier, R, Pepin, J, Verges, S, Parati, G, Perger E., Baillieul S., Esteve F., Pichon A., Bilo G., Soranna D., Doutreleau S., Savina Y., Ulliel-Roche M., Brugniaux J. V., Stauffer E., Oberholzer L., Howe C., Hannco I., Lombardi C., Tamisier R., Pepin J. -L., Verges S., and Parati G.

Abstract

Introduction: Chronic mountain sickness (CMS) is a condition characterized by excessive erythrocytosis in response to chronic hypobaric hypoxia. CMS frequently triggers cardiorespiratory diseases such as pulmonary hypertension and right or left heart failure. Ambient hypoxia might be further amplified night-time by intermittent hypoxia related to sleep-disordered breathing (SDB) so that sleep disturbance may be an important feature of CMS. Our aim was to characterize in a cross-sectional study nocturnal hypoxaemia, SDB, blood pressure (BP), arterial stiffness and carotid intima-media thickness (CIMT) in highlanders living at extreme altitude. Methods: Men aged 18 to 55 years were prospectively recruited. Home sleep apnoea test, questionnaires (short-form health survey; Montreal cognitive assessment; Pittsburgh Sleep Questionnaire Index and the Insomnia severity index), 24-h ambulatory BP monitoring, CIMT and arterial stiffness were evaluated in 3 groups: i) Andean lowlanders (sea-level); ii) highlanders living at 3,800 m and iii) highlanders living at 5,100 m. Analyses were conducted in sub-groups according to 1) CMS severity 2) healthy subjects living at the three different altitude. Results: Ninety-two males were evaluated at their living altitudes. Among the 54 highlanders living at 5,100 m, subjects with CMS showed lower mean nocturnal oxygen saturation (SpO2), SpO2 nadir, lower pulse wave velocity and higher nocturnal BP variability than those with no-CMS. Lower nocturnal SpO2 nadir was associated with higher CMS severity (ß= −0.14, p=.009). Among the 55 healthy subjects, healthy highlanders at 5,100 m were characterized by lower scores on quality of life and sleep quality scales and lower mean SpO2 compared to lowlanders. Conclusions: Lower nocturnal SpO2 and higher nocturnal BP variability are associated with CMS severity in individuals living permanently at high altitude. The role of lower SpO2 and higher nocturnal BP variability in the cardiovascular progre

Published
2022

25. Obstructive sleep apnoea in adult patients post-tonsillectomy

Author

Riha, R, Kotoulas, S, Pataka, A, Kvamme, J, Joppa, P, Hedner, J, Anttalainen, U, Barbe, F, Bonsignore, M, Basoglu, O, Bielicki, P, Bouloukaki, I, Dogas, Z, Dorkova, Z, Escourrou, P, Fietze, I, Esquinas, C, Grote, L, Kent, B, Lena, L, Lavie, P, Levy, P, Lombardi, C, Marrone, O, Masa, J, Mcnicholas, W, Montserrat, J, Parati, G, Penzel, T, Pepin, J, Plywaczewski, R, Pretl, M, Rodenstein, D, Roisman, G, Ryan, S, Saaresranta, T, Schiza, S, Schulz, R, Sliwinski, P, Staats, R, Steiropoulos, P, Tasbakan, M, Tkacova, R, Varoneckas, G, Verbraecken, J, Vitols, A, Vrints, H, Zielinski, J, Riha R. L., Kotoulas S. -. C., Pataka A., Kvamme J. A., Joppa P., Hedner J., Anttalainen U., Barbe F., Bonsignore M. R., Basoglu O., Bielicki P., Bouloukaki I., Dogas Z., Dorkova Z., Escourrou P., Fietze I., Esquinas C., Grote L., Kent B. D., Lena L., Lavie P., Levy P., Lombardi C., Marrone O., Masa J. F., McNicholas W. T., Montserrat J. M., Parati G., Penzel T., Pepin J. L., Plywaczewski R., Pretl M., Rodenstein D., Roisman G., Ryan S., Saaresranta T., Schiza S. E., Schulz R., Sliwinski P., Staats R., Steiropoulos P., Tasbakan M. S., Tkacova R., Varoneckas G., Verbraecken J., Vitols A., Vrints H., Zielinski J., Riha, R, Kotoulas, S, Pataka, A, Kvamme, J, Joppa, P, Hedner, J, Anttalainen, U, Barbe, F, Bonsignore, M, Basoglu, O, Bielicki, P, Bouloukaki, I, Dogas, Z, Dorkova, Z, Escourrou, P, Fietze, I, Esquinas, C, Grote, L, Kent, B, Lena, L, Lavie, P, Levy, P, Lombardi, C, Marrone, O, Masa, J, Mcnicholas, W, Montserrat, J, Parati, G, Penzel, T, Pepin, J, Plywaczewski, R, Pretl, M, Rodenstein, D, Roisman, G, Ryan, S, Saaresranta, T, Schiza, S, Schulz, R, Sliwinski, P, Staats, R, Steiropoulos, P, Tasbakan, M, Tkacova, R, Varoneckas, G, Verbraecken, J, Vitols, A, Vrints, H, Zielinski, J, Riha R. L., Kotoulas S. -. C., Pataka A., Kvamme J. A., Joppa P., Hedner J., Anttalainen U., Barbe F., Bonsignore M. R., Basoglu O., Bielicki P., Bouloukaki I., Dogas Z., Dorkova Z., Escourrou P., Fietze I., Esquinas C., Grote L., Kent B. D., Lena L., Lavie P., Levy P., Lombardi C., Marrone O., Masa J. F., McNicholas W. T., Montserrat J. M., Parati G., Penzel T., Pepin J. L., Plywaczewski R., Pretl M., Rodenstein D., Roisman G., Ryan S., Saaresranta T., Schiza S. E., Schulz R., Sliwinski P., Staats R., Steiropoulos P., Tasbakan M. S., Tkacova R., Varoneckas G., Verbraecken J., Vitols A., Vrints H., and Zielinski J.

Abstract

Background: The impact of removing the upper airway lymphoid tissue and in particular, tonsillectomy, in adults with OSA has not been demonstrated in large populations. Aims: To compare the severity of OSA and the prevalence of cardiovascular, metabolic and respiratory co-morbidities between patients with OSA who had undergone previous tonsillectomy and those who had not. Methods: The 19,711 participants in this study came from the European sleep apnea database (ESADA) which comprises data from unselected adult patients aged 18–80 years with a history of symptoms suggestive of OSA referred to sleep centers throughout Europe. Results: There were no differences between the two groups in terms of sex ratio and age (146 patients with previous tonsillectomy vs. 19565 patients without). Patients who had undergone tonsillectomy had a lower body mass index (29.3 ± 5.2 kg/m2 vs 32.2 ± 6.6 kg/m2, p < 0.001), lower subjective sleep latency (17.1 ± 17.8 min vs 25.5 ± 30.4 min, p = 0.001), lower ODI (15.7 ± 18.3 events/hour vs 30.7 ± 26.1 events/hour, p < 0.001), and SpO2<90% time during sleep (21.8 ± 47.5 min vs 52.6 ± 80.8 min, p < 0.001). OSA patients with tonsillectomy had a lower prevalence of Type II diabetes mellitus (p = 0.001), hypertension (p < 0.001) and a higher prevalence of hyperlipidemia (p < 0.001) and were less likely to be commenced on CPAP (p < 0.001). Conclusion: In a large population of almost 20,000 OSA patients from across Europe, patients who had undergone tonsillectomy presented with less severe OSA at time of diagnosis, and had a lower prevalence of Type II diabetes mellitus and cardiovascular co-morbidities.

Published
2021

26. The ANDANTE Project: A Worldwide Individual Data Meta-Analysis of the Effect of Sleep Apnea Treatment on Blood Pressure [El proyecto ANDANTE: un metanálisis a nivel mundial de datos individuales sobre el efecto del tratamiento de la apnea del sueño en la presión arterial]

Author

Pengo, M, Steier, J, Parati, G, Ayas, N, Barbe, F, Barnes, M, Campos-Rodriguez, F, Cistulli, P, Lloberes, P, Craig, S, Drager, L, Duran-Cantolla, J, Litvin and Evgeniya Elfimova, A, Esra, T, Giontella, A, Fava, C, Fuchs, S, Fuchs, F, Gagnadoux, F, Garcia-Rio, F, Javaheri and Daniel J Gottlieb, S, Hong, G, Grunstein, R, Hoyos, C, Joyeux-Faure, M, Liu, P, Lorenzi-Filho, G, Ip, M, Lui, M, Martinez-Garcia, M, Mcevoy, D, Mehra, R, Monasterio, C, Mcmillan, A, Morrell, M, Pamidi, S, Bilo, G, Lombardi, C, Peker, Y, Glos, M, Penzel, T, Pepin, J, Pepperell, J, Phillips, C, Quan, S, Quinnell, T, Salles, G, Salord, N, Sanchez-de-la-Torre, M, Irene Schwarz, E, Shaw, J, Shukla, G, Stradling, J, Thunstrom, E, Wang, J, Weaver, T, Zambon, A, Soranna, D, Zambra, G, Pengo M. F., Steier J., Parati G., Ayas N. T., Barbe F., Barnes M., Campos-Rodriguez F., Cistulli P., Lloberes P., Craig S., Drager L. F., Duran-Cantolla J., Litvin and Evgeniya Elfimova A., Esra T., Giontella A., Fava C., Fuchs S. C., Fuchs F. D., Gagnadoux F., Garcia-Rio F., Javaheri and Daniel J Gottlieb S., Hong G. -R., Grunstein R. R., Hoyos C. M., Joyeux-Faure M., Liu P. Y., Lorenzi-Filho G., Ip M. S. M., Lui M. M. S., Martinez-Garcia M. A., McEvoy D., Mehra R., Monasterio C., McMillan A., Morrell M. J., Pamidi S., Pengo M., Bilo G., Lombardi C., Peker Y., Glos M., Penzel T., Pepin J. -L., Pepperell J. C. T., Phillips C. L., Quan S. F., Quinnell T., Salles G. F., Salord N., Sanchez-de-la-Torre M., Irene Schwarz E., Shaw J. E., Shukla G., Stradling J., Thunstrom E., Wang J. -G., Weaver T. E., Zambon A., Soranna D., Zambra G., Pengo, M, Steier, J, Parati, G, Ayas, N, Barbe, F, Barnes, M, Campos-Rodriguez, F, Cistulli, P, Lloberes, P, Craig, S, Drager, L, Duran-Cantolla, J, Litvin and Evgeniya Elfimova, A, Esra, T, Giontella, A, Fava, C, Fuchs, S, Fuchs, F, Gagnadoux, F, Garcia-Rio, F, Javaheri and Daniel J Gottlieb, S, Hong, G, Grunstein, R, Hoyos, C, Joyeux-Faure, M, Liu, P, Lorenzi-Filho, G, Ip, M, Lui, M, Martinez-Garcia, M, Mcevoy, D, Mehra, R, Monasterio, C, Mcmillan, A, Morrell, M, Pamidi, S, Bilo, G, Lombardi, C, Peker, Y, Glos, M, Penzel, T, Pepin, J, Pepperell, J, Phillips, C, Quan, S, Quinnell, T, Salles, G, Salord, N, Sanchez-de-la-Torre, M, Irene Schwarz, E, Shaw, J, Shukla, G, Stradling, J, Thunstrom, E, Wang, J, Weaver, T, Zambon, A, Soranna, D, Zambra, G, Pengo M. F., Steier J., Parati G., Ayas N. T., Barbe F., Barnes M., Campos-Rodriguez F., Cistulli P., Lloberes P., Craig S., Drager L. F., Duran-Cantolla J., Litvin and Evgeniya Elfimova A., Esra T., Giontella A., Fava C., Fuchs S. C., Fuchs F. D., Gagnadoux F., Garcia-Rio F., Javaheri and Daniel J Gottlieb S., Hong G. -R., Grunstein R. R., Hoyos C. M., Joyeux-Faure M., Liu P. Y., Lorenzi-Filho G., Ip M. S. M., Lui M. M. S., Martinez-Garcia M. A., McEvoy D., Mehra R., Monasterio C., McMillan A., Morrell M. J., Pamidi S., Pengo M., Bilo G., Lombardi C., Peker Y., Glos M., Penzel T., Pepin J. -L., Pepperell J. C. T., Phillips C. L., Quan S. F., Quinnell T., Salles G. F., Salord N., Sanchez-de-la-Torre M., Irene Schwarz E., Shaw J. E., Shukla G., Stradling J., Thunstrom E., Wang J. -G., Weaver T. E., Zambon A., Soranna D., and Zambra G.

Published
2021

27. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39)

Author

Moore, K, Bookman, M, Sehouli, J, Miller, A, Anderson, C, Scambia, G, Myers, T, Taskiran, C, Robison, K, Maenpaa, J, Willmott, L, Colombo, N, Thomes-Pepin, J, Liontos, M, Gold, M, Garcia, Y, Sharma, S, Darus, C, Aghajanian, C, Okamoto, A, Wu, X, Safin, R, Wu, F, Molinero, L, Maiya, V, Khor, V, Lin, Y, Pignata, S, Moore K. N., Bookman M., Sehouli J., Miller A., Anderson C., Scambia G., Myers T., Taskiran C., Robison K., Maenpaa J., Willmott L., Colombo N., Thomes-Pepin J., Liontos M., Gold M. A., Garcia Y., Sharma S. K., Darus C. J., Aghajanian C., Okamoto A., Wu X., Safin R., Wu F., Molinero L., Maiya V., Khor V. K., Lin Y. G., Pignata S., Moore, K, Bookman, M, Sehouli, J, Miller, A, Anderson, C, Scambia, G, Myers, T, Taskiran, C, Robison, K, Maenpaa, J, Willmott, L, Colombo, N, Thomes-Pepin, J, Liontos, M, Gold, M, Garcia, Y, Sharma, S, Darus, C, Aghajanian, C, Okamoto, A, Wu, X, Safin, R, Wu, F, Molinero, L, Maiya, V, Khor, V, Lin, Y, Pignata, S, Moore K. N., Bookman M., Sehouli J., Miller A., Anderson C., Scambia G., Myers T., Taskiran C., Robison K., Maenpaa J., Willmott L., Colombo N., Thomes-Pepin J., Liontos M., Gold M. A., Garcia Y., Sharma S. K., Darus C. J., Aghajanian C., Okamoto A., Wu X., Safin R., Wu F., Molinero L., Maiya V., Khor V. K., Lin Y. G., and Pignata S.

Abstract

PURPOSE To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). METHODS This multicenter placebo-controlled double-blind randomized phase III trial (ClinicalTrials.gov identifier: NCT03038100) enrolled patients with newly diagnosed untreated International Federation of Gynecology and Obstetrics (FIGO) stage III or IV OC who either had undergone primary cytoreductive surgery with macroscopic residual disease or were planned to receive neoadjuvant chemotherapy and interval surgery. Patients were stratified by FIGO stage, Eastern Cooperative Oncology Group performance status, tumor immune cell PD-L1 staining, and treatment strategy and randomly assigned 1:1 to receive 3-weekly cycles of atezolizumab 1,200 mg or placebo (day 1, cycles 1-22), with paclitaxel plus carboplatin (day 1, cycles 1-6) plus bevacizumab 15 mg/kg (day 1, cycles 2-22), omitting perioperative bevacizumab in neoadjuvant patients. The co-primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat and PD-L1-positive populations. RESULTS Between March 8, 2017, and March 26, 2019, 1,301 patients were enrolled. The median progression-free survival was 19.5 versus 18.4 months with atezolizumab versus placebo, respectively (hazard ratio, 0.92; 95% CI, 0.79 to 1.07; stratified log-rank P 5.28), in the intention-to-treat population and 20.8 versus 18.5 months, respectively (hazard ratio, 0.80; 95% CI, 0.65 to 0.99; P 5.038), in the PD-L1-positive population. The interim (immature) overall survival results showed no significant benefit from atezolizumab. The most common grade 3 or 4 adverse events were neutropenia (21% with atezolizumab v 21% with placebo), hypertension (18% v 20%, respectively), and anemia (12% v 12%). CONCLUSION Current evidence does not support the use of immune checkpoint

Published
2021

29. Sleep characteristics and cardio-metabolic comorbidities in the OSA-COPD overlap syndrome: Data from the European Sleep Apnea Database (ESADA)

Author

van Zeller, M, primary, K. Basoglu, O, additional, Verbraecken, J, additional, Lombardi, C, additional, T. Mcnicholas, W, additional, Pepin, J L, additional, Steiropoulos, P, additional, Sliwinski, P, additional, Correia, D, additional, R. Bonsignore, M, additional, E. Schiza, S, additional, Hedner, J, additional, Grote, L, additional, and Drummond, M, additional

Published
2022
Full Text
View/download PDF

31. Management of Acute Exacerbations of COPD in the Intensive Care Unit: OUTCOMEREA Database 1997-2018

Author

Galerneau, L, primary, Bailly, S, additional, Terzi, N, additional, Ruckly, S, additional, Garrouste-Orgeas, M, additional, Cohen, Y, additional, Hong Tuan Ha, V, additional, Gainnier, M, additional, Siami, S, additional, Dupuis, C, additional, Darmon, M, additional, Azoulay, E, additional, Forel, J, additional, Sigaud, F, additional, Adrie, C, additional, Goldgran-Toledano, D, additional, Bruneel, F, additional, De Montmollin, E, additional, Argaud, L, additional, Reignier, J, additional, Pepin, J, additional, and Timsit, J, additional

Published
2022
Full Text
View/download PDF

34. Corticosteroid for acute exacerbations of COPD in ICU. A French Cohort: OUTCOMEREA database.

Author

Galerneau, L, primary, Bailly, S, additional, Terzi, N, additional, Ruckly, S, additional, Garrouste-Orgeas, M, additional, Cohen, Y, additional, Hong Tuan Ha, V, additional, Gainnier, M, additional, Siami, S, additional, Dupuis, C, additional, Darmon, M, additional, Azoulay, E, additional, Forel, J, additional, Sigaud, F, additional, Adrie, C, additional, Goldgran-Toledano, D, additional, Bruneel, F, additional, De Montmollin, E, additional, Argaud, L, additional, Reignier, J, additional, Pepin, J, additional, and Timsit, J, additional

Published
2022
Full Text
View/download PDF

35. Variabilité phénotypique et corrélations génotype-phénotype des dystrophinopathies : contribution des banques de données

Author

Humbertclaude, V., Hamroun, D., Picot, M.-C., Bezzou, K., Bérard, C., Boespflug-Tanguy, O., Bommelaer, C., Campana-Salort, E., Cances, C., Chabrol, B., Commare, M.-C., Cuisset, J.-M., de Lattre, C., Desnuelle, C., Echenne, B., Halbert, C., Jonquet, O., Labarre-Vila, A., N’Guyen-Morel, M.-A., Pages, M., Pepin, J.-L., Petitjean, T., Pouget, J., Ollagnon-Roman, E., Richelme, C., Rivier, F., Sacconi, S., Tiffreau, V., Vuillerot, C., Béroud, C., Tuffery-Giraud, S., and Claustres, M.

Published
2013
Full Text
View/download PDF

36. Sleep apnoea management in Europe during the COVID-19 pandemic – Data from the European Sleep Apnoea Database (ESADA)

Author

Grote, L, Mcnicholas, W, Hedner, J, Anttalainen, U, Saaresranta, T, Basoglu, O, Gunduz, C, Tasbakan, S, Bouloukaki, I, Schiza, S, Bonsignore, M, Marrone, O, Petitjean, M, Roisman, G, Fietze, I, Laharnar, N, Penzel, T, Zou, D, Kent, B, Ryan, S, Kvamme, J, Bailly, S, Pepin, J, Tamisier, R, Lombardi, C, Parati, G, Pataka, A, Plywaczewski, R, Sliwinski, P, Pretl, M, Riha, R, Staats, R, Steiropoulos, P, Joppa, P, Verbraecken, J, Petiet, E, Trakada, G, Ludka, O, Buskova, J, Hein, H, Drummond, M, van Zeller, M, Dogas, Z, Galic, T, Gouveris, H, Mihaicuta, S, Randerath, W, Herkenrath, S, Fanfulla, F, Testelmans, D, Grote L., McNicholas W. T., Hedner J., Anttalainen U., Saaresranta T., Basoglu O. K., Gunduz C., Tasbakan S., Bouloukaki I., Schiza S. E., Bonsignore M. R., Marrone O., Petitjean M., Roisman G., Fietze I., Laharnar N., Penzel T., Zou D., Kent B. D., Ryan S., Kvamme J. A., Bailly S., Pepin J. -L., Tamisier R., Lombardi C., Parati G., Pataka A., Plywaczewski R., Sliwinski P., Pretl M., Riha R., Staats R., Steiropoulos P., Joppa P., Verbraecken J., Petiet E., Trakada G., Ludka O., Buskova J., Hein H., Drummond M., van Zeller M., Dogas Z., Galic T., Gouveris H., Mihaicuta S., Randerath W., Herkenrath S., Fanfulla F., Testelmans D., Grote, L, Mcnicholas, W, Hedner, J, Anttalainen, U, Saaresranta, T, Basoglu, O, Gunduz, C, Tasbakan, S, Bouloukaki, I, Schiza, S, Bonsignore, M, Marrone, O, Petitjean, M, Roisman, G, Fietze, I, Laharnar, N, Penzel, T, Zou, D, Kent, B, Ryan, S, Kvamme, J, Bailly, S, Pepin, J, Tamisier, R, Lombardi, C, Parati, G, Pataka, A, Plywaczewski, R, Sliwinski, P, Pretl, M, Riha, R, Staats, R, Steiropoulos, P, Joppa, P, Verbraecken, J, Petiet, E, Trakada, G, Ludka, O, Buskova, J, Hein, H, Drummond, M, van Zeller, M, Dogas, Z, Galic, T, Gouveris, H, Mihaicuta, S, Randerath, W, Herkenrath, S, Fanfulla, F, Testelmans, D, Grote L., McNicholas W. T., Hedner J., Anttalainen U., Saaresranta T., Basoglu O. K., Gunduz C., Tasbakan S., Bouloukaki I., Schiza S. E., Bonsignore M. R., Marrone O., Petitjean M., Roisman G., Fietze I., Laharnar N., Penzel T., Zou D., Kent B. D., Ryan S., Kvamme J. A., Bailly S., Pepin J. -L., Tamisier R., Lombardi C., Parati G., Pataka A., Plywaczewski R., Sliwinski P., Pretl M., Riha R., Staats R., Steiropoulos P., Joppa P., Verbraecken J., Petiet E., Trakada G., Ludka O., Buskova J., Hein H., Drummond M., van Zeller M., Dogas Z., Galic T., Gouveris H., Mihaicuta S., Randerath W., Herkenrath S., Fanfulla F., and Testelmans D.

Published
2020

37. Long-term positive airway pressure therapy is associated with reduced total cholesterol levels in patients with obstructive sleep apnea: data from the European Sleep Apnea Database (ESADA)

Author

Gunduz, C, Basoglu, O, Kvamme, J, Verbraecken, J, Anttalainen, U, Marrone, O, Steiropoulos, P, Roisman, G, Joppa, P, Hein, H, Trakada, G, Hedner, J, Grote, L, Petiet, E, Montserrat, J, Fietze, I, Penzel, T, Ludka, O, Rodenstein, D, Masa, J, Bouloukaki, I, Schiza, S, Kent, B, Mcnicholas, W, Ryan, S, Riha, R, Schulz, R, Zou, D, Pepin, J, Levy, P, Bailly, S, Lavie, L, Lavie, P, Tasbakan, M, Varoneckas, G, Tkacova, R, Staats, R, Barbe, F, Lombardi, C, Parati, G, Drummond, M, van Zeller, M, Bonsignore, M, Petitjean, M, Pretl, M, Vitols, A, Dogas, Z, Galic, T, Pataka, A, Saaresranta, T, Plywaczewski, R, Sliwinski, P, Bielicki, P, Gunduz C., Basoglu O. K., Kvamme J. A., Verbraecken J., Anttalainen U., Marrone O., Steiropoulos P., Roisman G., Joppa P., Hein H., Trakada G., Hedner J., Grote L., Petiet E., Montserrat J. M., Fietze I., Penzel T., Ludka O., Rodenstein D., Masa J. F., Bouloukaki I., Schiza S., Kent B., McNicholas W. T., Ryan S., Riha R. L., Schulz R., Zou D., Pepin J. L., Levy P., Bailly S., Lavie L., Lavie P., Tasbakan M. S., Varoneckas G., Tkacova R., Staats R., Barbe F., Lombardi C., Parati G., Drummond M., van Zeller M., Bonsignore M. R., Petitjean M., Pretl M., Vitols A., Dogas Z., Galic T., Pataka A., Saaresranta T., Plywaczewski R., Sliwinski P., Bielicki P., Gunduz, C, Basoglu, O, Kvamme, J, Verbraecken, J, Anttalainen, U, Marrone, O, Steiropoulos, P, Roisman, G, Joppa, P, Hein, H, Trakada, G, Hedner, J, Grote, L, Petiet, E, Montserrat, J, Fietze, I, Penzel, T, Ludka, O, Rodenstein, D, Masa, J, Bouloukaki, I, Schiza, S, Kent, B, Mcnicholas, W, Ryan, S, Riha, R, Schulz, R, Zou, D, Pepin, J, Levy, P, Bailly, S, Lavie, L, Lavie, P, Tasbakan, M, Varoneckas, G, Tkacova, R, Staats, R, Barbe, F, Lombardi, C, Parati, G, Drummond, M, van Zeller, M, Bonsignore, M, Petitjean, M, Pretl, M, Vitols, A, Dogas, Z, Galic, T, Pataka, A, Saaresranta, T, Plywaczewski, R, Sliwinski, P, Bielicki, P, Gunduz C., Basoglu O. K., Kvamme J. A., Verbraecken J., Anttalainen U., Marrone O., Steiropoulos P., Roisman G., Joppa P., Hein H., Trakada G., Hedner J., Grote L., Petiet E., Montserrat J. M., Fietze I., Penzel T., Ludka O., Rodenstein D., Masa J. F., Bouloukaki I., Schiza S., Kent B., McNicholas W. T., Ryan S., Riha R. L., Schulz R., Zou D., Pepin J. L., Levy P., Bailly S., Lavie L., Lavie P., Tasbakan M. S., Varoneckas G., Tkacova R., Staats R., Barbe F., Lombardi C., Parati G., Drummond M., van Zeller M., Bonsignore M. R., Petitjean M., Pretl M., Vitols A., Dogas Z., Galic T., Pataka A., Saaresranta T., Plywaczewski R., Sliwinski P., and Bielicki P.

Abstract

Background and aim: Obstructive sleep apnea (OSA) is an independent risk factor for dyslipidemia. The current study examined the effects of positive airway pressure (PAP) treatment on lipid status in the European Sleep Apnea Database (ESADA). Methods: The prospective cohort study enrolled 1564 OSA subjects (74% male, mean age 54 ± 11y, body mass index (BMI) 32.7 ± 6.6 kg/m2 and apnea-hypopnea index (AHI) 40.3 ± 24.4 n/h) undergoing PAP therapy for at least three months (mean 377.6 ± 419.5 days). Baseline and follow-up total cholesterol (TC) from nine centers were analyzed. Repeated measures and logistic regression tests (adjusted for age, sex, weight changes, lipid lowering medication, PAP compliance, and treatment duration) were used to compare changes in TC concentration. Incident risk for a coronary heart disease event (CHD) was used to compute a Framingham CHD risk score (estimated from age, BMI, blood pressure, and TC). Results: Adjusted means of TC decreased from 194.2 mg/dl to 189.3 mg/dl during follow-up (p = 0.019). A clinically significant (10%) reduction of TC at PAP follow-up was observed in 422 patients (27%). Duration of PAP therapy was identified as independent predictor for TC reduction, which implies an approximately 10% risk reduction for incident CHD events (from 26.7% to 24.1% in men and from 11.2% to 10.1% in women, p < 0.001 respectively). Conclusion: This observational study demonstrates a reduction of TC after long-term PAP treatment. The close association between TC concentration and cardiovascular (CV) mortality suggests that identification and treatment of OSA may have a beneficial effect on overall CV risk due to this mechanism. This possibility needs to be evaluated in prospective randomized studies.

Published
2020

38. Subjects with venous insufficiency have high risk of obstructive sleep apnea in relationship to fluid shift

Author

Perger, E, Blaise, S, Vermorel, C, Boge, G, Pepin, J, Redolfi, S, Bosson, J, Perger E., Blaise S., Vermorel C., Boge G., Pepin J. L., Redolfi S., Bosson J. L., Perger, E, Blaise, S, Vermorel, C, Boge, G, Pepin, J, Redolfi, S, Bosson, J, Perger E., Blaise S., Vermorel C., Boge G., Pepin J. L., Redolfi S., and Bosson J. L.

Abstract

Background: Obstructive sleep apnea (OSA) is highly prevalent in conditions characterized by fluid overload. Chronic venous insufficiency (CVI) is associated to fluid overload that might interfere with OSA occurrence and severity. Methods: A total of 180 patients with symptomatic CVI completed the Berlin questionnaire and were assessed for the presence of symptoms and signs of OSA and fluid shift. Results: According to the Berlin questionnaire, 59 patients (33%) had high risk of OSA. The predictors of having a positive Berlin questionnaire were male sex, body mass index and symptoms possibly related to fluid shift. Conclusions: Patients with CVI, a disease characterized by fluid overload, present high risk of OSA, which might be related to fluid shift.

Published
2020

39. Periodic limb movements during sleep and blood pressure changes in sleep apnoea: Data from the European Sleep Apnoea Database

Author

Lombardi, C, Parati, G, Soranna, D, Zambon, A, Sliwinski, P, Roisman, G, Pepin, J, Schiza, S, Riha, R, Joppa, P, Fietze, I, Hedner, J, Grote, L, Anttalainen, U, Barbe, F, Bonsignore, M, Basoglu, O, Bielicki, P, Dogas, Z, Dorkova, Z, Escourrou, P, Hein, H, Kvamme, J, Levy, P, Marrone, O, Masa, J, Mcnicholas, W, Montserrat, J, Pataka, A, Penzel, T, Petiet, E, Plywaczewski, R, Pretl, M, Ryan, S, Saaresranta, T, Schulz, R, Tasbakan, M, Tkacova, R, Staats, R, Steiropoulos, P, Varoneckas, G, Verbraecken, J, Lombardi C., Parati G., Soranna D., Zambon A., Sliwinski P., Roisman G., Pepin J. -L., Schiza S., Riha R., Joppa P., Fietze I., Hedner J., Grote L., Anttalainen U., Barbe F., Bonsignore M. R., Basoglu O. K., Bielicki P., Dogas Z., Dorkova Z., Escourrou P., Hein H., Kvamme J. A., Levy P., Marrone O., Masa J. F., McNicholas W. T., Montserrat J. M., Pataka A., Penzel T., Petiet E., Pepin J. L., Plywaczewski R., Pretl M., Riha R. L., Ryan S., Saaresranta T., Schulz R., Tasbakan M. S., Tkacova R., Staats R., Steiropoulos P., Varoneckas G., Verbraecken J., Lombardi, C, Parati, G, Soranna, D, Zambon, A, Sliwinski, P, Roisman, G, Pepin, J, Schiza, S, Riha, R, Joppa, P, Fietze, I, Hedner, J, Grote, L, Anttalainen, U, Barbe, F, Bonsignore, M, Basoglu, O, Bielicki, P, Dogas, Z, Dorkova, Z, Escourrou, P, Hein, H, Kvamme, J, Levy, P, Marrone, O, Masa, J, Mcnicholas, W, Montserrat, J, Pataka, A, Penzel, T, Petiet, E, Plywaczewski, R, Pretl, M, Ryan, S, Saaresranta, T, Schulz, R, Tasbakan, M, Tkacova, R, Staats, R, Steiropoulos, P, Varoneckas, G, Verbraecken, J, Lombardi C., Parati G., Soranna D., Zambon A., Sliwinski P., Roisman G., Pepin J. -L., Schiza S., Riha R., Joppa P., Fietze I., Hedner J., Grote L., Anttalainen U., Barbe F., Bonsignore M. R., Basoglu O. K., Bielicki P., Dogas Z., Dorkova Z., Escourrou P., Hein H., Kvamme J. A., Levy P., Marrone O., Masa J. F., McNicholas W. T., Montserrat J. M., Pataka A., Penzel T., Petiet E., Pepin J. L., Plywaczewski R., Pretl M., Riha R. L., Ryan S., Saaresranta T., Schulz R., Tasbakan M. S., Tkacova R., Staats R., Steiropoulos P., Varoneckas G., and Verbraecken J.

Abstract

Background and objective: OSA and PLMS are known to induce acute BP swings during sleep. Our current study aimed to address the independent effect of PLMS on BP in an unselected OSA patient cohort. Methods: This cross-sectional analysis included 1487 patients (1110 males, no previous hypertension diagnosis or treatment, mean age: 52.5 years, mean BMI: 30.5 kg/m2) with significant OSA (defined as AHI ≥ 10) recruited from the European Sleep Apnoea Cohort. Patients underwent overnight PSG. Patients were stratified into two groups: patients with significant PLMS (PLMSI > 25 events/hour of sleep) and patients without significant PLMS (PLMSI < 25 events/hour of sleep). SBP, DBP and PP were the variables of interest. For each of these, a multivariate regression linear model was fitted to evaluate the relationship between PLMS and outcome adjusting for sociodemographic and clinical covariates (gender, age, BMI, AHI, ESS, diabetes, smoking and sleep efficiency). Results: The univariate analysis of SBP showed an increment of BP equal to 4.70 mm Hg (P < 0.001) in patients with significant PLMS compared to patients without significant PLMS. This increment remained significant after implementing a multivariate regression model (2.64 mm Hg, P = 0.044). No significant increment of BP was observed for DBP and PP. Conclusion: PLMS is associated with a rise in SBP regardless of AHI, independent of clinical and sociodemographic confounders. A PLMS phenotype may carry an increased risk for cardiovascular disease in OSA patients.

Published
2020

40. LBA32 A randomized, phase II, dose optimization of gotistobart, a pH-sensitive anti-CTLA-4, in combination with standard dose pembrolizumab in platinum-resistant recurrent ovarian cancer: Safety, efficacy and dose optimization (PRESERVE-004/GOG-3081)

Author

Barlin, J.N., Lim, P.C., Thomes Pepin, J., Hopp, E.E., Cloven, N.G., Lee, C., Eshed, H.D., Black, D., Cottrill, H.M., Hand, L., O'Malley, D.M., Chuang, L.T., Willmott, L., Chisamore, M., Shpyro, S., Durbin, J., Zheng, P., Liu, Y., and Monk, B.J.

Published
2024
Full Text
View/download PDF

41. 746P Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression

Author

Coffman, L. Gardner, You, B., Hamilton, E.P., Garcia, Y. Garcia, Moore, K.N., Sonnenburg, D., Scambia, G., Derio, S., Pepin, J. Thomes, Klasa-Mazurkiewicz, D., Tromp, J., Breuer, S., Weroha, S., Sukhina, O., Wang, Y., Stec, J.J., and Van Gorp, T.

Published
2024
Full Text
View/download PDF

47. Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in the Intensive Care Unit: The Outcomerea Database, 1997-2018

Author

Galerneau, L.-M., primary, Bailly, S., additional, Terzi, N., additional, Ruckly, S., additional, Garrouste-Orgeas, M., additional, Cohen, Y., additional, Hong Tuan Ha, V., additional, Gainnier, M., additional, Siami, S., additional, Dupuis, C., additional, Darmon, M., additional, Forel, J.-M., additional, Rigault, G., additional, Adrie, C., additional, Laurent, V., additional, Goldgran-Toledano, D., additional, de Montmollin, E., additional, Argaud, L., additional, Reignier, J., additional, Pepin, J.-L., additional, and Timsit, J.-F., additional

Published
2022
Full Text
View/download PDF

49. The ANDANTE Project: A Worldwide Individual Data Meta-Analysis of the Effect of Sleep Apnea Treatment on Blood Pressure [El proyecto ANDANTE: un metanálisis a nivel mundial de datos individuales sobre el efecto del tratamiento de la apnea del sueño en la presión arterial]

Author

Pengo M. F., Steier J., Parati G., Ayas N. T., Barbe F., Barnes M., Campos-Rodriguez F., Cistulli P., Lloberes P., Craig S., Drager L. F., Duran-Cantolla J., Litvin and Evgeniya Elfimova A., Esra T., Giontella A., Fava C., Fuchs S. C., Fuchs F. D., Gagnadoux F., Garcia-Rio F., Javaheri and Daniel J Gottlieb S., Hong G. -R., Grunstein R. R., Hoyos C. M., Joyeux-Faure M., Liu P. Y., Lorenzi-Filho G., Ip M. S. M., Lui M. M. S., Martinez-Garcia M. A., McEvoy D., Mehra R., Monasterio C., McMillan A., Morrell M. J., Pamidi S., Pengo M., Bilo G., Lombardi C., Peker Y., Glos M., Penzel T., Pepin J. -L., Pepperell J. C. T., Phillips C. L., Quan S. F., Quinnell T., Salles G. F., Salord N., Sanchez-de-la-Torre M., Irene Schwarz E., Shaw J. E., Shukla G., Stradling J., Thunstrom E., Wang J. -G., Weaver T. E., Zambon A., Soranna D., Zambra G., Pengo, M, Steier, J, Parati, G, Ayas, N, Barbe, F, Barnes, M, Campos-Rodriguez, F, Cistulli, P, Lloberes, P, Craig, S, Drager, L, Duran-Cantolla, J, Litvin and Evgeniya Elfimova, A, Esra, T, Giontella, A, Fava, C, Fuchs, S, Fuchs, F, Gagnadoux, F, Garcia-Rio, F, Javaheri and Daniel J Gottlieb, S, Hong, G, Grunstein, R, Hoyos, C, Joyeux-Faure, M, Liu, P, Lorenzi-Filho, G, Ip, M, Lui, M, Martinez-Garcia, M, Mcevoy, D, Mehra, R, Monasterio, C, Mcmillan, A, Morrell, M, Pamidi, S, Bilo, G, Lombardi, C, Peker, Y, Glos, M, Penzel, T, Pepin, J, Pepperell, J, Phillips, C, Quan, S, Quinnell, T, Salles, G, Salord, N, Sanchez-de-la-Torre, M, Irene Schwarz, E, Shaw, J, Shukla, G, Stradling, J, Thunstrom, E, Wang, J, Weaver, T, Zambon, A, Soranna, D, and Zambra, G

Subjects
hypertension, blood pressure, sleep apnea
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results